Electrocardiographic response to intravenous urography: prospective evaluation of 275 patients.
A total of 275 consecutive patients referred for intravenous urography were monitored for electrocardiographic changes during administration of Conray 400 or Renovist II in the form of either intravenous bolus or infusion. Three patients who received Conray (two bolus and one infusion) developed sustained ventricular tachycardia; they reverted to sinus rhythm with intravenous lidocaine. A statistically significant (P less than .05) number of patients developed a heart rate increase of 10 beats/min or more with bolus of either drug (65 of 128) compared to infusion (21 of 147). Depression of ST segment (greater than or equal to 0.5 mm) was encountered statistically more often (P less than .05) with bolus (20 of 128) compared to infusion (six of 147). Increase of corrected QT of 0.10 sec or more was observed more often (P less than .05) with bolus (43 of 128) compared to infusion (five of 147). Abnormal resting ECG, coronary artery disease, or congestive heart failure imposed a higher (P less than .05) risk for development of ventricular tachycardia, ST depression, or ectopic ventricular beats. It is concluded that a bolus injection be very cautiously administered to patients with risk factors such as abnormal ECG, coronary artery disease, or congestive heart failure during intravenous urography and that resuscitative facilities be available.